-
1
-
-
0034999148
-
The burden of illness of cancer: Economic cost and quality of life
-
Brown ML, Lipscomb J, Zinder C. The burden of illness of cancer: economic cost and quality of life. Annu Rev Public Health. 2001;22:91-113.
-
(2001)
Annu Rev Public Health.
, vol.22
, pp. 91-113
-
-
Brown, M.L.1
Lipscomb, J.2
Zinder, C.3
-
2
-
-
44049106563
-
Cost of care for elderly cancer patients in the United States
-
Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, Brown ML. Cost of care for elderly cancer patients in the United States. J Natl Canc Inst. 2008;100:630-41.
-
(2008)
J Natl Canc Inst.
, vol.100
, pp. 630-641
-
-
Yabroff, K.R.1
Lamont, E.B.2
Mariotto, A.3
Warren, J.L.4
Topor, M.5
Meekins, A.6
Brown, M.L.7
-
3
-
-
33846956479
-
The forest and the trees: The human costs of cancer
-
Kessler LG, Ramsey SD. The forest and the trees: the human costs of cancer. J Natl Canc Inst. 2007;99:2-3.
-
(2007)
J Natl Canc Inst.
, vol.99
, pp. 2-3
-
-
Kessler, L.G.1
Ramsey, S.D.2
-
4
-
-
33748133711
-
Cancer of unknown primary site
-
De Vita VT, editor. 7th ed. Philadelphia: Lippincott, Williams & Wilkins
-
Greco FA, Hainsworth JD. Cancer of unknown primary site. In: de Vita VT, editor. Cancer principles and practice of oncology. 7th ed. Philadelphia: Lippincott, Williams & Wilkins; 2005. p. 2213-36.
-
(2005)
Cancer principles and practice of oncology
, pp. 2213-2236
-
-
Greco, F.A.1
Hainsworth, J.D.2
-
5
-
-
16244396701
-
The value of postmortem examination in cases of metastases of unknown origin -20 years retrospective data from a tertiary care center
-
Al-Brahim N, Ross C, Carter B, Chorneyko K. The value of postmortem examination in cases of metastases of unknown origin -20 years retrospective data from a tertiary care center. Ann Diagn Pathol. 2005;9:77-80.
-
(2005)
Ann Diagn Pathol.
, vol.9
, pp. 77-80
-
-
Al-Brahim, N.1
Ross, C.2
Carter, B.3
Chorneyko, K.4
-
7
-
-
27744523250
-
Tumor markers in breast cancer. European Group on Tumor Markers recommendations
-
Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in breast cancer. European Group on Tumor Markers recommendations. Tumor Biol. 2005;26:281-93.
-
(2005)
Tumor Biol.
, vol.26
, pp. 281-293
-
-
Molina, R.1
Barak, V.2
Van Dalen, A.3
Duffy, M.J.4
Einarsson, R.5
Gion, M.6
-
8
-
-
34249881055
-
Tumour markers in colorectal cancer: European Group on Tumor Markers (EGTM) guidelines for clinical use
-
Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder R, Klapdor R, et al. Tumour markers in colorectal cancer: European Group on Tumor Markers (EGTM) guidelines for clinical use. Eur J Cancer. 2007;43:1348-60.
-
(2007)
Eur J Cancer.
, vol.43
, pp. 1348-1360
-
-
Duffy, M.J.1
Van Dalen, A.2
Haglund, C.3
Hansson, L.4
Holinski-Feder, R.5
Klapdor, R.6
-
9
-
-
28944450024
-
CA 125 in ovarian cancer: European group on tumor markers guidelines for clinical use
-
Duffy MJ, Bonfrer JM, Kulpas J, Rustin GJ, Soletormos G, Torre GC, et al. CA 125 in ovarian cancer: European group on tumor markers guidelines for clinical use. Int J Gynecol Canc. 2005;15:679-91.
-
(2005)
Int J Gynecol Canc.
, vol.15
, pp. 679-691
-
-
Duffy, M.J.1
Bonfrer, J.M.2
Kulpas, J.3
Rustin, G.J.4
Soletormos, G.5
Torre, G.C.6
-
10
-
-
55349134617
-
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers
-
Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008;54:11-79.
-
(2008)
Clin Chem.
, vol.54
, pp. 11-79
-
-
Sturgeon, C.M.1
Duffy, M.J.2
Stenman, U.H.3
Lilja, H.4
Brunner, N.5
Chan, D.W.6
-
11
-
-
36849069347
-
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer
-
Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287-312.
-
(2007)
J Clin Oncol.
, vol.25
, pp. 5287-5312
-
-
Harris, L.1
Fritsche, H.2
Mennel, R.3
Norton, L.4
Ravdin, P.5
Taube, S.6
-
12
-
-
11144356618
-
New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)
-
Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, et al. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Canc Inst. 2004;96:487-8.
-
(2004)
J Natl Canc Inst.
, vol.96
, pp. 487-488
-
-
Rustin, G.J.1
Quinn, M.2
Thigpen, T.3
Du Bois, A.4
Pujade-Lauraine, E.5
Jakobsen, A.6
-
13
-
-
70349862783
-
Tumor markers in pancreatic cancer: A European Group on Tumor Markers (EGTM) status report
-
Duffy MH, Sturgeon C, Lamer R, Haglund C, Holubec VL, Klapdor R, et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol. 2010;21:441-7.
-
(2010)
Ann Oncol.
, Issue.21
, pp. 441-447
-
-
Duffy, M.H.1
Sturgeon, C.2
Lamer, R.3
Haglund, C.4
Holubec, V.L.5
Klapdor, R.6
-
14
-
-
33846595479
-
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer
-
Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313-27.
-
(2006)
J Clin Oncol.
, Issue.24
, pp. 5313-5327
-
-
Locker, G.Y.1
Hamilton, S.2
Harris, J.3
Jessup, J.M.4
Kemeny, N.5
Macdonald, J.S.6
-
15
-
-
0344826667
-
Prospective evaluation of squamous cell carcinoma and carcinoembryonic antigen as prognostic factors in patients with cervical cancer
-
Molina R, Filella X, Lejarcegui JA, Pahisa A, Torne A, Rovirosa B, et al. Prospective evaluation of squamous cell carcinoma and carcinoembryonic antigen as prognostic factors in patients with cervical cancer. Tumor Biol. 2003;24:156-64.
-
(2003)
Tumor Biol.
, vol.24
, pp. 156-164
-
-
Molina, R.1
Filella, X.2
Lejarcegui, J.A.3
Pahisa, A.4
Torne, A.5
Rovirosa, B.6
-
16
-
-
0029069469
-
Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients
-
Molina R, Zanon G, Filella X, Moreno F, Daniels M, Zanon G, et al. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Br Canc Res Treat. 1995;36:41-8.
-
(1995)
Br Canc Res Treat.
, vol.36
, pp. 41-48
-
-
Molina, R.1
Zanon, G.2
Filella, X.3
Moreno, F.4
Daniels, M.5
Zanon, G.6
-
17
-
-
33751534935
-
Role of serum tumor markers in monitoring for recurrence of gastric cancer following radical gastrectomy
-
Choi S, Jang J, Lee J, Roh MH, Kim MC, Lee WS, et al. Role of serum tumor markers in monitoring for recurrence of gastric cancer following radical gastrectomy. Dig Dis Sci. 2006;51:2081-6.
-
(2006)
Dig Dis Sci.
, vol.51
, pp. 2081-2086
-
-
Choi, S.1
Jang, J.2
Lee, J.3
Roh, M.H.4
Kim, M.C.5
Lee, W.S.6
-
18
-
-
53249123632
-
-
4th ed. Geneva World Health Organization
-
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stelin H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Geneva: World Health Organization; 2008.
-
(2008)
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
-
-
Swerdlow, S.H.1
Campo, E.2
Harris, N.L.3
Jaffe, E.S.4
Pileri, S.A.5
Stelin, H.6
-
19
-
-
0027431788
-
Incidence of pleural effusion in a well-defined region: Epidemiology study in central Bohemia
-
Maurel M, Arustova M, Stansy B, Light RW. Incidence of pleural effusion in a well-defined region: epidemiology study in central Bohemia. Chest. 1993;104:1486-9.
-
(1993)
Chest.
, vol.104
, pp. 1486-1489
-
-
Maurel, M.1
Arustova, M.2
Stansy, B.3
Light, R.W.4
-
20
-
-
0001239316
-
Malignant pleural and pericardial effusions
-
De Vita VT, Hellman S, Rosenberg SA, editors. 5th ed. Philadelphia: Lippincott-Raven
-
Pass HI. Malignant pleural and pericardial effusions. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven; p. 2586-98.
-
Cancer Principles and Practice of Oncology
, pp. 2586-2598
-
-
Pass, H.I.1
-
21
-
-
0002122822
-
Malignant ascites
-
De Vita VT, Hellman S, Rosenberg SA, editors. 5th ed. Philadelphia: Lippincott-Raven
-
Maringola FM, Schwartzentruber DJ. Malignant ascites. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven; p. 2598-606.
-
Cancer Principles and Practice of Oncology
, pp. 2598-2606
-
-
Maringola, F.M.1
Schwartzentruber, D.J.2
-
22
-
-
0037115537
-
Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site
-
Culine S, Kramar A, Saghatchion M, Bugat R, Lesimple T, Latholary A, et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol. 2002;20:4679-83.
-
(2002)
J Clin Oncol.
, vol.20
, pp. 4679-4683
-
-
Culine, S.1
Kramar, A.2
Saghatchion, M.3
Bugat, R.4
Lesimple, T.5
Latholary, A.6
-
23
-
-
1442350528
-
Clinical and immunohistochemical analysis of patients with unknown primary tumor. A search for prognostic factors in UPT
-
Van de Wouw AJ, Jansen RLH, Griffionen AW, Hillen HFP. Clinical and immunohistochemical analysis of patients with unknown primary tumor. A search for prognostic factors in UPT. Anticancer Res. 2004;24:297-302.
-
(2004)
Anticancer Res.
, vol.24
, pp. 297-302
-
-
Van De Wouw, A.J.1
Jansen, R.L.H.2
Griffionen, A.W.3
Hillen, H.F.P.4
-
24
-
-
57049085895
-
Mucins CA 125, CA 199, CA 15.3, and TAG 72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE
-
Molina R, Auge JM, Bosch X, Escudero JM, Marrades R, Vĩolas N, et al. Mucins CA 125, CA 199, CA 15.3, and TAG 72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE. Tumor Biol. 2008;29:371-80.
-
(2008)
Tumor Biol.
, vol.29
, pp. 371-380
-
-
Molina, R.1
Auge, J.M.2
Bosch, X.3
Escudero, J.M.4
Marrades, R.5
Vĩolas, N.6
-
25
-
-
33846918200
-
CEA, CA 19.9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice
-
Duraker N, Hot S, Polat Y, Höbek N, Gençler N, Urhan N. CEA, CA 19.9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol. 2007;95:142-7.
-
(2007)
J Surg Oncol.
, vol.95
, pp. 142-147
-
-
Duraker, N.1
Hot, S.2
Polat, Y.3
Höbek, N.4
Gençler, N.5
Urhan, N.6
-
26
-
-
84863433967
-
Clinical evaluation of the simultaneous determination of tumor markers in fluid and serum and their ratio in the differential diagnosis of serous effusions
-
Trape J, Molina R, Sant F. Clinical evaluation of the simultaneous determination of tumor markers in fluid and serum and their ratio in the differential diagnosis of serous effusions. Tumor Biol. 2005;51:219-22.
-
(2005)
Tumor Biol.
, vol.51
, pp. 219-222
-
-
Trape, J.1
Molina, R.2
Sant, F.3
-
27
-
-
66449111135
-
Usefulness of serum tumor markers, including progastrinreleasing peptide in patients with lung cancer: Correlation with histology
-
Molina R, Auge JM, Bosch X, Escudero JM, Vĩolas N, Marrades R, et al. Usefulness of serum tumor markers, including progastrinreleasing peptide in patients with lung cancer: correlation with histology. Tumor Biol. 2009;30:121-9.
-
(2009)
Tumor Biol.
, vol.30
, pp. 121-129
-
-
Molina, R.1
Auge, J.M.2
Bosch, X.3
Escudero, J.M.4
Vĩolas, N.5
Marrades, R.6
-
28
-
-
0026600508
-
Tumor associated glycoprotein-72 (TAG-72) levels in patients with non-malignant and malignant diseases
-
Filella X, Molina R, Jo J, Bedini JL, Joseph J, Ballesta AM. Tumor associated glycoprotein-72 (TAG-72) levels in patients with non-malignant and malignant diseases. Bull Cancer. 1992;79:271-7.
-
(1992)
Bull Cancer.
, vol.79
, pp. 271-277
-
-
Filella, X.1
Molina, R.2
Jo, J.3
Bedini, J.L.4
Joseph, J.5
Ballesta, A.M.6
-
29
-
-
0025021755
-
SCC antigen measured in malignant and non malignant diseases
-
Molina R, Filella X, Torres MD, Ballesta AM, Mengual P, Cases A, Balague A. SCC antigen measured in malignant and non malignant diseases. Clin Chem. 1990;36:251-4.
-
(1990)
Clin Chem.
, vol.36
, pp. 251-254
-
-
Molina, R.1
Filella, X.2
Torres, M.D.3
Ballesta, A.M.4
Mengual, P.5
Cases, A.6
Balague, A.7
-
30
-
-
0025992203
-
Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases
-
Molina R, Filella X, Bruix J, Mengual PJ, Bosch J, Calvet X, et al. Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem. 1991;37:1379-83.
-
(1991)
Clin Chem.
, vol.37
, pp. 1379-1383
-
-
Molina, R.1
Filella, X.2
Bruix, J.3
Mengual, P.J.4
Bosch, J.5
Calvet, X.6
-
31
-
-
37249086687
-
False positive findings for tumors markers after curative gastrectomy for gastric cancer
-
Ohtsuka T, Sato S, Kitajima Y. False positive findings for tumors markers after curative gastrectomy for gastric cancer. Dig Dis Sci. 2008;53:73-9.
-
(2008)
Dig Dis Sci.
, vol.53
, pp. 73-79
-
-
Ohtsuka, T.1
Sato, S.2
Kitajima, Y.3
-
32
-
-
0026053915
-
Tumor markers in chronic renal failure and hemodialysis patients
-
Cases A, Filella X, Molina R, Ballesta AM, Lopez-Revert JL, Revert L. Tumor markers in chronic renal failure and hemodialysis patients. Nephron. 1991;57:183-6.
-
(1991)
Nephron.
, vol.57
, pp. 183-186
-
-
Cases, A.1
Filella, X.2
Molina, R.3
Ballesta, A.M.4
Lopez-Revert, J.L.5
Revert, L.6
-
33
-
-
13844311017
-
Increased serum CA 15.3 levels in patients with megaloblastic anemia due to vitamin B12 deficiency
-
Symeonides A, Kouraklis-Symeonides A, Apostolopoulos D, Arvanitopoulou E, Giannakoulas N, Vassilakos P, et al. Increased serum CA 15.3 levels in patients with megaloblastic anemia due to vitamin B12 deficiency. Oncology. 2004;67:359-67.
-
(2004)
Oncology.
, vol.67
, pp. 359-367
-
-
Symeonides, A.1
Kouraklis-Symeonides, A.2
Apostolopoulos, D.3
Arvanitopoulou, E.4
Giannakoulas, N.5
Vassilakos, P.6
-
34
-
-
10444263784
-
Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions
-
Porcel JM, Vives M, Esquerda A, Salud A, Perez B, Rodriguez- Panadero F. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest. 2004;126:1757-63.
-
(2004)
Chest.
, vol.126
, pp. 1757-1763
-
-
Porcel, J.M.1
Vives, M.2
Esquerda, A.3
Salud, A.4
Perez, B.5
Rodriguez-Panadero, F.6
-
35
-
-
0032727907
-
Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions
-
Miédougé M, Rouzaud P, Salama G, Pujazon MC, Vincent C, Mauduyl MA, et al. Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions. Br J Cancer. 1999;81:1059-61.
-
(1999)
Br J Cancer.
, vol.81
, pp. 1059-1061
-
-
Miédougé, M.1
Rouzaud, P.2
Salama, G.3
Pujazon, M.C.4
Vincent, C.5
Mauduyl, M.A.6
-
36
-
-
49549124785
-
Humoral autoimmune responses to the squamous cell carcinoma antigen protein family in psoriasis
-
El-Rachkidy RG, Young HS, Griffiths CE, Camp RD. Humoral autoimmune responses to the squamous cell carcinoma antigen protein family in psoriasis. J Invest Dermatol. 2008;128:2219-24.
-
(2008)
J Invest Dermatol.
, vol.128
, pp. 2219-2224
-
-
El-Rachkidy, R.G.1
Young, H.S.2
Griffiths, C.E.3
Camp, R.D.4
-
37
-
-
63349097914
-
New horny layer marker proteins for evaluating skin condition in atopic dermatitis
-
Yamane Y,Moriyama K, Yasuda C, Miyata S, AiharaM, Ikezawa Z, et al. New horny layer marker proteins for evaluating skin condition in atopic dermatitis. Int Arch Allergy Immunol. 2009;150:89-101.
-
(2009)
Int Arch Allergy Immunol.
, vol.150
, pp. 89-101
-
-
Yamane, Y.1
Moriyama, K.2
Yasuda, C.3
Miyata, S.4
Aihara, M.5
Ikezawa, Z.6
-
38
-
-
0042423723
-
AFP-producing gastric carcinoma: Multivariate analysis of prognostic factors in 270 patients
-
Adachi Y, Tsuchihashi J, Shiraishi N, Yasuda K, Etoh T, Kitano S. AFP-producing gastric carcinoma: multivariate analysis of prognostic factors in 270 patients. Oncology. 2003;65:95-101.
-
(2003)
Oncology.
, vol.65
, pp. 95-101
-
-
Adachi, Y.1
Tsuchihashi, J.2
Shiraishi, N.3
Yasuda, K.4
Etoh, T.5
Kitano, S.6
-
39
-
-
0141533136
-
The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: A prospective clinical study
-
Takahashi Y, Takeuchi T, Sakamoto J, Touge T, Mai M, Ohkura H, et al. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer. 2003;6:142-5.
-
(2003)
Gastric Cancer.
, vol.6
, pp. 142-145
-
-
Takahashi, Y.1
Takeuchi, T.2
Sakamoto, J.3
Touge, T.4
Mai, M.5
Ohkura, H.6
-
40
-
-
33748133963
-
Tumor-marker analysis and verification of prognostic models in patients with cancer of unknown primary, receiving platinum-based combination chemotherapy
-
Yonemori K, Ando M, Shibata T, Katsumata N, Matsumoto K, Yamanaka Y, et al. Tumor-marker analysis and verification of prognostic models in patients with cancer of unknown primary, receiving platinum-based combination chemotherapy. J Canc Res Clin Oncol. 2006;132:635-42.
-
(2006)
J Canc Res Clin Oncol.
, vol.132
, pp. 635-642
-
-
Yonemori, K.1
Ando, M.2
Shibata, T.3
Katsumata, N.4
Matsumoto, K.5
Yamanaka, Y.6
-
41
-
-
0030446523
-
Elevated germ cell markers in carcinoma of uncertain primary site do not predict response to platinum based chemotherapy
-
Currow DC, Findlay M, Cox K, Harnette PR. Elevated germ cell markers in carcinoma of uncertain primary site do not predict response to platinum based chemotherapy. Eur J Cancer. 1996;32:2357-9.
-
(1996)
Eur J Cancer.
, vol.32
, pp. 2357-2239
-
-
Currow, D.C.1
Findlay, M.2
Cox, K.3
Harnette, P.R.4
-
42
-
-
0036124183
-
Tumormarkers in metastatic disease from cancer of unknown primary origin
-
Milovic M, Popov I, Jelic S. Tumormarkers in metastatic disease from cancer of unknown primary origin. Med Sci Mon. 2002;8:25-30.
-
(2002)
Med Sci Mon.
, vol.8
, pp. 25-30
-
-
Milovic, M.1
Popov, I.2
Jelic, S.3
-
44
-
-
33846899259
-
Investigations for bone metastases from an unknown primary
-
Destombe CL, Botton E, Le Gal G, Roudaut A, Jousse-Joulin S, Devauchelle-Pensec V, Saraux A. Investigations for bone metastases from an unknown primary. Joint Bone Spine. 2007;74:85-9.
-
(2007)
Joint Bone Spine.
, vol.74
, pp. 85-89
-
-
Destombe, C.L.1
Botton, E.2
Le Gal, G.3
Roudaut, A.4
Jousse-Joulin, S.5
Devauchelle-Pensec, V.6
Saraux, A.7
-
45
-
-
10444240305
-
Tumor markers in undiagnosed pleural effusions
-
Light RW. Tumor markers in undiagnosed pleural effusions. Chest. 2004;126:1721-2.
-
(2004)
Chest.
, vol.126
, pp. 1721-1722
-
-
Light, R.W.1
-
46
-
-
27144452535
-
Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer
-
Lee JH, Chang JH. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer. Chest. 2005;128:2298-303.
-
(2005)
Chest.
, vol.128
, pp. 2298-2303
-
-
Lee, J.H.1
Chang, J.H.2
-
47
-
-
20844446971
-
Tumor antigen markers for the detection of solid cancers in inflammatory myopathies
-
Amoura Z, Duhaut P, Huong DL, Wechsler B, Costedoat- Charlumeau N, Frances C, et al. Tumor antigen markers for the detection of solid cancers in inflammatory myopathies. Canc Epidemiol Biomarkers Prev. 2005;14:1279-82.
-
(2005)
Canc Epidemiol Biomarkers Prev.
, vol.14
, pp. 1279-1282
-
-
Amoura, Z.1
Duhaut, P.2
Huong, D.L.3
Wechsler, B.4
Costedoat-Charlumeau, N.5
Frances, C.6
|